What is the recommended treatment for Helicobacter pylori infection in an adult patient without known drug allergies?

H. pylori Treatment

First-Line Treatment: Bismuth Quadruple Therapy for 14 Days

Bismuth quadruple therapy for 14 days is the definitive first-line treatment for H. pylori infection, achieving 80-90% eradication rates regardless of local clarithromycin resistance patterns. 1, 2, 3

Regimen Components

• High-dose PPI twice daily (esomeprazole or rabeprazole 40 mg preferred) taken 30 minutes before meals on an empty stomach 1, 2, 3
• Bismuth subsalicylate 262 mg (2 tablets) four times daily 1, 2, 3
• Metronidazole 500 mg three to four times daily (total 1.5-2 g/day) 1, 2, 3
• Tetracycline 500 mg four times daily 1, 2, 3
• Duration: 14 days mandatory (extending from 7 to 14 days improves eradication by approximately 5%) 1, 2, 3, 4

Why Bismuth Quadruple Therapy Is First-Line

• Clarithromycin resistance now exceeds 15-20% across North America and most of Europe, reducing traditional triple therapy success to only ~70% 1, 2, 3
• When clarithromycin-resistant strains are present, triple therapy eradication drops from ~90% to ~20% 1, 3
• Bismuth quadruple therapy achieves 80-90% eradication even against dual clarithromycin-metronidazole resistant strains 1, 2, 3
• No bacterial resistance to bismuth has been documented 5, 1, 3
• Bismuth's synergistic effect overcomes metronidazole resistance in vitro 5, 1

Alternative First-Line Options (Restricted Use Only)

Concomitant Non-Bismuth Quadruple Therapy

• Use only when bismuth is unavailable AND local clarithromycin resistance is documented <15% 1, 2, 3
• High-dose PPI twice daily + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for 14 days 1, 2, 3

Clarithromycin Triple Therapy

• Use only in regions with documented clarithromycin resistance <15% AND no prior macrolide exposure 1, 2, 3
• High-dose PPI twice daily + clarithromycin 500 mg twice daily + amoxicillin 1000 mg twice daily for 14 days 1, 2, 3
• Do not use empirically in North America or most of Europe where resistance exceeds 15-20% 1, 2, 3

Second-Line Treatment After First-Line Failure

After Bismuth Quadruple Therapy Failure

• Levofloxacin triple therapy for 14 days (provided no prior fluoroquinolone exposure): high-dose PPI twice daily + amoxicillin 1000 mg twice daily + levofloxacin 500 mg once daily 5, 1, 2, 3
• Levofloxacin resistance rates are rising (11-30% primary, 19-30% secondary), so never use as first-line 1, 3

After Clarithromycin Triple Therapy Failure

• Bismuth quadruple therapy for 14 days (if not previously used) 5, 1, 2, 3
• Never repeat clarithromycin after failure—resistance develops rapidly and eradication drops from 90% to 20% 5, 1, 2, 3

Third-Line and Rescue Therapies

• After two documented eradication failures with confirmed adherence, obtain antibiotic susceptibility testing to guide further treatment 5, 1, 2, 3, 4

Rescue Options

• Rifabutin triple therapy for 14 days: rifabutin 150 mg twice daily + amoxicillin 1000 mg twice daily + high-dose PPI twice daily (rifabutin resistance is rare) 1, 2, 3, 4
• High-dose dual therapy for 14 days: amoxicillin 2-3 g daily divided into 3-4 doses + high-dose PPI twice daily 1, 2, 3

Critical Optimization Factors

PPI Dosing

• High-dose PPI twice daily is mandatory—once-daily dosing is a major cause of treatment failure 1, 2, 3
• Esomeprazole or rabeprazole 40 mg twice daily increases cure rates by 8-12% compared to standard-dose PPIs 1, 2, 3
• Avoid pantoprazole 40 mg—it provides acid suppression equivalent to only ~9 mg omeprazole and yields inferior outcomes 1, 2, 3
• Take PPI 30 minutes before meals on an empty stomach without concomitant antacids 1, 2, 3

Treatment Duration

• 14 days is the evidence-based standard for all H. pylori regimens—endorsed by Toronto Consensus, Maastricht V/Florence, and American College of Gastroenterology 1, 2, 3, 4
• Shortening therapy below 14 days reduces eradication success by approximately 5% 1, 2, 3, 4

Special Populations

Penicillin Allergy

• Bismuth quadruple therapy is the first choice (contains tetracycline, not amoxicillin) 5, 1, 2, 3
• Consider penicillin allergy testing after first-line failure—most reported allergies are not true allergies, and amoxicillin resistance remains rare (<5%) 1, 2, 3
• If confirmed allergy and bismuth unavailable: PPI + clarithromycin + metronidazole for 14 days only where clarithromycin resistance <15% 5, 2, 3

Confirmation of Eradication

• Test at least 4 weeks after completing therapy using urea breath test or validated monoclonal stool antigen test 1, 2, 3
• Discontinue PPI at least 2 weeks (preferably 7-14 days) before testing to avoid false-negative results 1, 2, 3
• Never use serology for test-of-cure—antibodies persist long after successful treatment 1, 2, 3

Common Pitfalls to Avoid

• Never use once-daily PPI dosing 1, 2, 3
• Never shorten therapy below 14 days 1, 2, 3, 4
• Never repeat clarithromycin or levofloxacin after a failed regimen—resistance develops rapidly 5, 1, 2, 3
• Do not assume low clarithromycin resistance without local surveillance data—most regions now have high resistance 1, 2, 3
• Metronidazole can be reused with bismuth due to synergistic effects; amoxicillin and tetracycline can be reused because resistance remains rare 1, 2, 3
• Do not use levofloxacin empirically as first-line therapy 1, 2, 3